Abstract:Background In resectable oesophageal squamous cell carcinoma (ESCC), the eff i cacy of camrelizumab combined with chemotherapy and apatinib followed by minimally invasive oesophagectomy is not clear. We aimed to fi ll this knowledge gap. Methods This investigator-initiated, single-arm, prospective, phase 2 trial was performed at the Second Aff i liated Hospital of Zhejiang University, China. Patients (aged 18 - 75 years) who were histologically or cytologically diagnosed with ESCC were deemed suitable to participate in this trial. Patients received 2 - 3 cycles of neoadjuvant therapy with camrelizumab, nedaplatin, albumin paclitaxel, and apatinib; each cycle was repeated every 14 days. Surgery occurred 4 - 6 weeks after the last neoadjuvant treatment cycle. The primary outcome was the pathological complete response (PCR) rate of the tumour and lymph nodes. The changes in the peripheral blood immunopro fi le among patients without PCR (ie, non-PCR [NPCR]) and with PCR were assessed by mass cytometry. This study was registered with ClinicalTrials.gov, NCT04666090. Findings 42 patients were enrolled between November 23, 2020 and December 31, 2022. The disease control rate was 100.0% (95% CI, 91.6 - 100%), and the objective response rate was 83.3% (95% CI, 68.6 - 93.0%). Six (14.3%) patients experienced grade 3 adverse events. The most common were white blood cell count decrease (31.0%), alopecia (81.0%), asthenia (38.1%), and reactive cutaneous capillary endothelial proliferation (35.7%). 41 patients received minimally invasive oesophagectomy; all 41patients achieved R0 resection, and 18 (43.9%, 95% CI, 28.5 - 60.3%) patients achieved PCR. The median follow-up was 23 months and the 2-year survival rate was 85.9%. T-cell subsets in both the PCR and NPCR groups exhibited consistency in response to neoadjuvant therapy. In contrast, some of natural killer (NK) cells (NK-C03, NK-C11), B cells (B -C06) and monocytes (M -C05), exhibited signi fi cant differences between the PCR and NPCR groups before neoadjuvant therapy. M -C06 had a signi fi cant difference in the PCR group and NPCR group after neoadjuvant therapy. NK-C12 and B -C15 showed signi fi cant differences both before and after neoadjuvant therapy. Interpretation The application of camrelizumab, chemotherapy and apatinib in the neoadjuvant setting for locally advanced ESCC has shown promising antitumour activity and an acceptable safety pro fi le in this single-arm study. In the neoadjuvant setting, NK cell, B cell, and monocyte subsets exhibited greater predictive power for immunotherapy responsiveness than T-cell subsets. Longer follow-up to assess survival outcomes and a phase 3 randomised trial are needed to further evaluate the proposed treatment.

A study of neoadjuvant sintilimab combined with chemotherapy TP for locally advanced esophageal squamous cell carcinoma (ESCC).

Sintilimab in Patients with Advanced Esophageal Squamous Cell Carcinoma Refractory to Previous Chemotherapy: A Randomized, Open-Label Phase II Trial (ORIENT-2).

Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced resectable esophageal squamous cell carcinoma: A prospective phase 2 study.

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial

Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE)

175P A Study of Neoadjuvant Sintilimab Combined with Triplet Chemotherapy of Lipo-Paclitaxel, Cisplatin, and S-1 for Resectable Esophageal Squamous Cell Carcinoma (ESCC)

Sintilimab Plus Oxaliplatin/capecitabine (capeox) As Neoadjuvant Therapy in Patients with Locally Advanced, Resectable Gastric (g)/esophagogastric Junction (GEJ) Adenocarcinoma.

Tislelizumab in Combination with Chemotherapy for the Treatment of Chinese Patients (pts) with Esophageal Squamous Cell Carcinoma (ESCC): Results from One Cohort of an Ongoing Phase 2 Study.

Camrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Oesophageal Squamous Cell Carcinoma: a Single-Arm Phase 2 Trial

Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study

The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced lymph node-positive esophageal squamous cell carcinoma: A real world study.

Sintilimab combined with definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: A single-arm, multicenter, phase 2 trial.

Phase Ib Study of Sintilimab in Combination with Chemotherapy for 1L Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial

Mid-term follow-up results of neoadjuvant sintilimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma

The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in elderly patients with locally advanced esophageal squamous cell carcinoma.

Comparison of Efficacy and Safety of First-Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-Analysis

The Safety and Efficacy of Immune Checkpoint Inhibitor in Combination with FOLFOX As Neoadjuvant/adjuvant Therapy in Patients with Locally Advanced Colon Cancer.

Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial

A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study)

520. EFFICACY AND SAFETY OF NEOADJUVANT CHEMOTHERAPY AND IMMUNOTHERAPY IN LOCALLY RESECTABLE ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA